Safety and efficacy of nivolumab in patients with advanced Non–small-cell lung cancer treated beyond progression

B Ricciuti, C Genova, M Bassanelli, A De Giglio… - Clinical Lung Cancer, 2019 - Elsevier
Introduction Treatment with immune checkpoint inhibitors beyond progression is associated
with improved survival in patients with melanoma and clear-cell renal carcinoma. Whether …
被引用次数：48 相关文章

Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression

B Ricciuti, C Genova, M Bassanelli… - CLINICAL LUNG …, 2019 - cris.unibo.it
The possibility of delayed immune-related responses implies that patients who experience
progressive disease may benefit from treatment with immunotherapy beyond progression …

Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression

B Ricciuti, C Genova, M Bassanelli… - Clinical Lung …, 2019 - clinical-lung-cancer.com
Introduction Treatment with immune checkpoint inhibitors beyond progression is associated
with improved survival in patients with melanoma and clear-cell renal carcinoma. Whether …

Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression

B Ricciuti, C Genova, M Bassanelli… - Clinical lung …, 2019 - pubmed.ncbi.nlm.nih.gov
Introduction Treatment with immune checkpoint inhibitors beyond progression is associated
with improved survival in patients with melanoma and clear-cell renal carcinoma. Whether …

Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.

B Ricciuti, C Genova, M Bassanelli, A De Giglio… - Clinical Lung …, 2019 - europepmc.org
INTRODUCTION: Treatment with immune checkpoint inhibitors beyond progression is
associated with improved survival in patients with melanoma and clear-cell renal carcinoma …

Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression

B Ricciuti, C Genova, M Bassanelli… - CLINICAL LUNG …, 2019 - irinsubria.uninsubria.it
The possibility of delayed immune-related responses implies that patients who experience
progressive disease may benefit from treatment with immunotherapy beyond progression …